PL EN


Preferences help
enabled [disable] Abstract
Number of results
2006 | 54 | 3 | 165-172
Article title

Impact of fetal -maternal tolerance in hematopoietic stem cell transplantation

Title variants
Languages of publication
EN
Abstracts
EN
Allogeneic hematopoietic stem cell transplantation (HSCT) is known to cure various hematological disorders; however, its widespread use is limited due to a lack of histocompatible donors. Reciprocal cell traffic between the mother and fetus during pregnancy gives rise to postpartum fetal-maternal lymphohematopoietic microchimerism, which is frequently detected in the blood or tissue of healthy individuals. Studies in clinical and experimental transplantation provide evidence that exposure to non-inherited maternal antigens (NIMAs) during pregnancy may result in long-lasting fetomaternal microchimerism and tolerance induction. Studies of HLA-mismatched HSCT have suggested a relatively lower incidence of severe graft-versus-host disease (GVHD) after transplantation from a NIMA-mismatched donor. Studies using a mouse model have also demonstrated a 'child-to-mother' bone marrow transplantation from an NIMA-exposed donor to reduce the morbidity and mortality of GVHD in an antigen-specific manner while preserving the graft-versus-leukemia effects and favoring the immune reconstitution, thus resulting in a marked improvement in outcome after HSCT. Prospective clinical studies are therefore warranted to confirm these beneficial effects of fetal-maternal tolerance in allogeneic HSCT.
Contributors
author
author
author
References
Document Type
REVIEW
Publication order reference
Takanori Teshima, M.D., Center for Cellular and Molecular Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-7e799ffb-a6fa-3168-9bdc-507c23e105cc
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.